Propeller Health, GSK Expand Collaboration for COPD and Asthma Inhaler Devices

Propeller Health and GlaxoSmithKline (GSK) will extend their collaboration in which patients with chronic obstructive pulmonary disease (COPD) and asthma use Propeller’s clip-on sensor and software platform with GSK’s Ellipta Inhaler to help them manage their illnesses.

The new extended partnership, first announced in 2015, will allow Propeller and GSK to commercialize Propeller’s digital respiratory health management system in conjunction with the Ellipta inhaler.

GSK has been developing medicines to manage COPD and asthma for the past 45 years. Propeller develops sensors, mobile apps and services that help improve the quality of life for people with chronic respiratory diseases.

Propeller’s extended collaboration with GSK follows last year’s successful CE marking in Europe and U.S. Food and Drug Administration (FDA) 510(k) class II clearance of Propeller’s sensor and software program to be used with the Ellipta Inhaler.

The sensor registers use of the inhaler. Propeller’s software platform analyzes that data and presents it to patients and clinicians through data-driven digital interfaces.

“We are excited to be working closely with GSK to make the sensor for the Ellipta inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the U.S.,” David Van Sickle, CEO and co-founder of Propeller, said in a press release. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”

Propeller’s software is widely used throughout the United States, and is compatible with most inhaler devices used by COPD and asthma patients including controller and reliever metered dose inhalers, as well as dry powder inhalers and soft mist inhalers.

“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” said Eric Dube, GSK’s senior vice-president and head of its global respiratory franchise. “We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”